MX378264B - Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. - Google Patents

Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Info

Publication number
MX378264B
MX378264B MX2018001499A MX2018001499A MX378264B MX 378264 B MX378264 B MX 378264B MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 378264 B MX378264 B MX 378264B
Authority
MX
Mexico
Prior art keywords
liquid polymer
drugs
delivery system
polymer delivery
extended administration
Prior art date
Application number
MX2018001499A
Other languages
English (en)
Other versions
MX2018001499A (es
Inventor
John Middleton
John Milton Downing
Vipin Saxena
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of MX2018001499A publication Critical patent/MX2018001499A/es
Publication of MX378264B publication Critical patent/MX378264B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Las composiciones farmacéuticas de polímero líquido con un poliéster líquido biodegradable que tiene un grupo terminal ácido carboxílico, un solvente biocompatible, y un agente farmacéutico activo, son útiles para ser administrados en el cuerpo para proveer una liberación prolongada ampliada del fármaco.
MX2018001499A 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. MX378264B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
MX2018001499A MX2018001499A (es) 2018-08-01
MX378264B true MX378264B (es) 2025-03-10

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001499A MX378264B (es) 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Country Status (19)

Country Link
US (3) US10786515B2 (es)
EP (2) EP3804698B1 (es)
JP (1) JP6949820B2 (es)
KR (1) KR102696721B1 (es)
CN (1) CN107920988B (es)
AU (1) AU2016302252B2 (es)
BR (1) BR112018002414B1 (es)
CA (1) CA2994704A1 (es)
DK (1) DK3331495T3 (es)
EA (1) EA036951B1 (es)
ES (2) ES2975519T3 (es)
HR (1) HRP20201991T1 (es)
HU (1) HUE052832T2 (es)
IL (1) IL257221B (es)
MX (1) MX378264B (es)
PT (1) PT3331495T (es)
TW (1) TWI718168B (es)
WO (1) WO2017024027A1 (es)
ZA (1) ZA201800591B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
EP3804698B1 (en) 2015-08-03 2024-01-31 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
EP3790574A4 (en) 2018-05-30 2022-07-13 Purdue Research Foundation TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
UY38386A (es) 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
WO2021064550A1 (en) 2019-09-30 2021-04-08 Tolmar International Limited Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CA3197170A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
KR20240079177A (ko) * 2022-11-28 2024-06-04 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
TW202440148A (zh) * 2022-12-23 2024-10-16 大陸商長春金賽藥業有限責任公司 ＧｎＲＨ拮抗劑可注射組合物及其製備方法和用途
TW202432169A (zh) * 2023-02-10 2024-08-16 美商托馬股份有限公司 輔美康（degarelix）有機溶劑調配物
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
PT1635875E (pt) 2003-06-26 2008-12-09 Psivida Inc Sistema de libertação de um fármaco com gelificação in situ
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2006278328A1 (en) 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
AU2007207618B2 (en) * 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
PL2323623T3 (pl) 2008-08-12 2017-04-28 Novartis Ag Kompozycje farmaceutyczne
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2389413A1 (en) * 2009-01-23 2011-11-30 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
IL254370B2 (en) 2009-04-24 2023-12-01 Iceutica Pty Ltd Production of coated nanoparticles with a high particle volume
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
PL2859887T3 (pl) 2010-07-09 2017-10-31 Innocore Tech B V Biodegradowalne segmentowane kopolimery wieloblokowe z rozdziałem faz oraz uwalnianie biologicznie czynnych polipeptydów
WO2012060267A1 (ja) * 2010-11-04 2012-05-10 新日鐵化学株式会社 ハードコート層付ポリカーボネート
EP2643009A4 (en) 2010-11-24 2015-04-01 Durect Corp COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
DK2691079T3 (da) 2011-03-31 2020-09-28 Ingell Tech Holding B V Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
RS60051B1 (sr) * 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
EP2768544A4 (en) * 2011-10-17 2015-06-24 Poly Med Inc ABSORBABLE IN SITU-MELAGING SYSTEM, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
WO2015165976A1 (en) 2014-05-01 2015-11-05 Ingell Technologies Holding B.V. Liquid triblock copolymer
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP3804698B1 (en) 2015-08-03 2024-01-31 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11752099B2 (en) 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents

Also Published As

Publication number Publication date
ES2975519T3 (es) 2024-07-08
CA2994704A1 (en) 2017-02-09
EP3804698A1 (en) 2021-04-14
US11779589B2 (en) 2023-10-10
HRP20201991T1 (hr) 2021-02-05
CN107920988A (zh) 2018-04-17
NZ739674A (en) 2024-10-25
AU2016302252B2 (en) 2022-01-20
JP6949820B2 (ja) 2021-10-13
EP3804698B1 (en) 2024-01-31
WO2017024027A1 (en) 2017-02-09
BR112018002414A2 (pt) 2018-09-18
TW201717960A (zh) 2017-06-01
AU2016302252A1 (en) 2018-02-22
CN107920988B (zh) 2021-08-17
PT3331495T (pt) 2020-12-07
KR20180030413A (ko) 2018-03-22
MX2018001499A (es) 2018-08-01
BR112018002414B1 (pt) 2023-11-21
IL257221A (en) 2018-03-29
DK3331495T3 (da) 2020-12-14
EA036951B1 (ru) 2021-01-19
ZA201800591B (en) 2021-07-28
TWI718168B (zh) 2021-02-11
IL257221B (en) 2022-01-01
US20240066039A1 (en) 2024-02-29
US20210060036A1 (en) 2021-03-04
EP3331495B1 (en) 2020-11-04
ES2836805T3 (es) 2021-06-28
EP3331495A1 (en) 2018-06-13
HUE052832T2 (hu) 2021-05-28
JP2018522906A (ja) 2018-08-16
EA201890436A1 (ru) 2018-09-28
US12447158B2 (en) 2025-10-21
KR102696721B1 (ko) 2024-08-19
HK1255638A1 (en) 2019-08-23
US20180214459A1 (en) 2018-08-02
US10786515B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
MX2021001118A (es) Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
WO2012035429A3 (en) Remotely controlled drug delivery systems
MX2015012887A (es) Composiciones de un poliortoester y un solvente aprotico.
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
EP4512394A3 (en) Dosage forms and use thereof
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
WO2011112996A3 (en) Injectable drug delivery system
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
PE20160534A1 (es) Sistema de administracion intrauterina
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EP3801703A4 (en) Tissue integrated drug delivery system
CR20140358A (es) Sistema para la administración de fármacos
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos
RU2726625C2 (ru) Фармацевтическая композиция, включающая полипептид
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form